
KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- The Ongoing Challenges Causing Need for Reform in Retail Pharmacy July 3, 2025As state-level PBM reform heats up amid dire situations for many retail pharmacies, Walgreens Chief Pharmacy Officer Rick Gates joins Drug Topics to discuss ongoing industry challenges.
- Smart Insulin Pen Cap System Shows Sustained Glycemic Improvement Over 12 Months | ADA 2025 July 2, 2025Patients who used the Bigfoot Unity Diabetes Management System had glycemic control and reduced diabetes distress.
- Q&A: Pharmacist Highlights Challenges in Vaccine Information Navigation Amid Changing Recommendations July 2, 2025Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, discusses the impact of shifting guidance on vaccination strategies.
- Dispensing Leadership: Navigating Your Pharmacy Career with Purpose July 2, 2025This episode explores how pharmacists can navigate their careers with clarity and purpose by grounding themselves in their professional oath, organizational mission, and core values.
- Q&A: Expert Discusses Impact of New ACIP Member Changes and Vaccine Recommendations July 2, 2025As concerns mount over potential shifts in vaccine recommendations, Deanna Tran, PharmD, BCACP, FAPhA, advocates for rigorous data assessment and patient-centered communication strategies.
- Q&A: Pharmacy Modernization Through Use of AI, Micro-Fulfillment July 2, 2025In part 3 of our interview with Walgreens Chief Pharmacy Officer Rick Gates, he explores the future of pharmacy practices and how modern use of technologies like AI are becoming commonplace.
- Taking The Lead: Pharmacy Leadership Essentials July 2, 2025
- Taking Charge of Your Career: Professional Development Opportunities for Technicians July 2, 2025
- GLP-1s Effective as Adjunctive Therapy in Patients with T1D, Obesity | ADA 2025 July 2, 2025Researchers explored patients with type 1 diabetes and overweight or obesity to understand the efficacy and safety of GLP-1s as adjunctive therapies.
- Q&A: The Evolving Role Pharmacists Play in Team-Based Diabetes Care | ADA 2025 July 2, 2025In a recap of his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter, RPh, discussed the role of pharmacists in team-based diabetes care.
Pharmacy Times articles
- Adjusting Asthma Management After Achieving Control on Long-Term Biologic Therapy July 3, 2025
- Reinventing Transplant Care: From Inpatient Tradition to Outpatient Innovation July 3, 2025LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.
- Expanding Access: Digital Therapeutics and the Evolving Role of Pharmacists July 3, 2025Expert explores the expanding role of FDA-approved Prescription Digital Therapeutics (PDTs).
- Protecting Older Adults from Severe RSV: Key Challenges and the Importance of Prevention July 3, 2025An expert discusses the challenges of diagnosing and treating RSV in older adults and highlights the critical role of prevention.
- Navigating CDC Recommendations for Pneumococcal Vaccines and Contraindications July 3, 2025An expert discusses how pharmacists should follow CDC immunization schedules for different age groups and use shared clinical decision-making for patients with prior vaccination history, while considering contraindications primarily related to severe allergic reactions to vaccine components.
- Breaking Down Pneumococcal Conjugate vs Polysaccharide Vaccines July 3, 2025An expert discusses how the 5 FDA-approved pneumococcal vaccines differ, with newer conjugate vaccines like PCV20 and PCV21 offering broader serotype coverage and better immune memory compared with the older polysaccharide vaccine, though geographic factors may influence vaccine selection.
- FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia July 2, 2025The letter cited deficiencies previously identified at a third-party manufacturing vendor unrelated to oxylanthanum carbonate (OLC).
- Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women July 2, 2025Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.
- Study Examines How Vitamin C Shapes Skin Health Through TET-Mediated Demethylation July 2, 2025Vitamin C enhances skin health by promoting epidermal cell growth and regeneration, offering a potential solution for aging and thinning skin.
- The Future of Top-Selling Biologics: Biosimilars on the Rise July 2, 2025

Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com